TY - JOUR
T1 - Age disparities in stage-specific colon cancer survival across seven countries
T2 - An International Cancer Benchmarking Partnership SURVMARK-2 population-based study
AU - Pilleron, Sophie
AU - Charvat, Hadrien
AU - Araghi, Marzieh
AU - Arnold, Melina
AU - Fidler-Benaoudia, Miranda M.
AU - Bardot, Aude
AU - Grønlie Guren, Marianne
AU - Tervonen, Hanna
AU - Little, Alana
AU - O'Connell, Dianne L.
AU - Gavin, Anna
AU - De, Prithwish
AU - Aagard Thomsen, Linda
AU - Møller, Bjørn
AU - Jackson, Christopher
AU - Bucher, Oliver
AU - Walsh, Paul M.
AU - Vernon, Sally
AU - Bray, Freddie
AU - Soerjomataram, Isabelle
N1 - Publisher Copyright:
© 2020 Union for International Cancer Control
PY - 2021/4/1
Y1 - 2021/4/1
N2 - We sought to understand the role of stage at diagnosis in observed age disparities in colon cancer survival among people aged 50 to 99 years using population-based cancer registry data from seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom. We used colon cancer incidence data for the period 2010 to 2014. We estimated the 3-year net survival, as well as the 3-year net survival conditional on surviving at least 6 months and 1 year after diagnosis, by country and stage at diagnosis (categorised as localised, regional or distant) using flexible parametric excess hazard regression models. In all countries, increasing age was associated with lower net survival. For example, 3-year net survival (95% confidence interval) was 81% (80-82) for 50 to 64 year olds and 58% (56-60) for 85 to 99 year olds in Australia, and 74% (73-74) and 39% (39-40) in the United Kingdom, respectively. Those with distant stage colon cancer had the largest difference in colon cancer survival between the youngest and the oldest patients. Excess mortality for the oldest patients with localised or regional cancers was observed during the first 6 months after diagnosis. Older patients diagnosed with localised (and in some countries regional) stage colon cancer who survived 6 months after diagnosis experienced the same survival as their younger counterparts. Further studies examining other prognostic clinical factors such as comorbidities and treatment, and socioeconomic factors are warranted to gain further understanding of the age disparities in colon cancer survival.
AB - We sought to understand the role of stage at diagnosis in observed age disparities in colon cancer survival among people aged 50 to 99 years using population-based cancer registry data from seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom. We used colon cancer incidence data for the period 2010 to 2014. We estimated the 3-year net survival, as well as the 3-year net survival conditional on surviving at least 6 months and 1 year after diagnosis, by country and stage at diagnosis (categorised as localised, regional or distant) using flexible parametric excess hazard regression models. In all countries, increasing age was associated with lower net survival. For example, 3-year net survival (95% confidence interval) was 81% (80-82) for 50 to 64 year olds and 58% (56-60) for 85 to 99 year olds in Australia, and 74% (73-74) and 39% (39-40) in the United Kingdom, respectively. Those with distant stage colon cancer had the largest difference in colon cancer survival between the youngest and the oldest patients. Excess mortality for the oldest patients with localised or regional cancers was observed during the first 6 months after diagnosis. Older patients diagnosed with localised (and in some countries regional) stage colon cancer who survived 6 months after diagnosis experienced the same survival as their younger counterparts. Further studies examining other prognostic clinical factors such as comorbidities and treatment, and socioeconomic factors are warranted to gain further understanding of the age disparities in colon cancer survival.
KW - cancer survival
KW - epidemiology
KW - older adults
KW - population-based cancer registry
UR - http://www.scopus.com/inward/record.url?scp=85092591250&partnerID=8YFLogxK
U2 - 10.1002/ijc.33326
DO - 10.1002/ijc.33326
M3 - Article
C2 - 33006395
AN - SCOPUS:85092591250
SN - 0020-7136
VL - 148
SP - 1575
EP - 1585
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 7
ER -